Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: cBR96-doxorubicin immunoconjugate|DRUG: docetaxel
Sponsor: Seagen Inc.